快捷搜索:

药明康德入选《麻省理工科技谈论》“50家智慧的公司”榜单

上海,2019年6月29日——本日,国际权势巨子科技媒体《麻省理工科技谈论》(MIT Technology Review)发布了2019年“50家智慧公司”(TR 50)评比成果。药明康德通过其奇特的开放式医药研发赋能平台,,帮忙全球客户加速新药研发进程,因此乐成入选该权势巨子榜单。

药明康德入选《麻省理工科技谈论》“50家智慧的公司”榜单

《麻省理工科技谈论》是一家具有全球影响力的良好科技类媒体,2010 年起设立“50家智慧公司”榜单,每年城市按照“高精尖科技创新和乐成贸易模式”两个焦点指标,从全球规模内评比出最具代表性的公司。该榜单揭示了已往一年新兴科技为整个世界所带来的创新厘革与冲破,已成为全球最权势巨子的贸易技能声誉榜单之一。

“50家智慧的公司”榜单旨在表扬那些可以或许智慧地将技能创新与贸易模式创新有用联合,并取得要害性进展的公司。《麻省理工科技谈论》TR50榜单评委会暗示:“药明康德缔造性地成立了开放式、一体化的医药研发赋能平台,对全球医药研发范畴的厘革和成长发生了努力影响。”

“感激《麻省理工科技谈论》对药明康德的承认,”药明康德董事长兼首席执行官李革博士暗示,“我们的任务是让任何人、任何公司都可以或许通过药明康德的赋能平台实现新药研发的创新空想。将来,我们将继续致力于帮忙全球客户晋升研发效率,让更多新药早日进入市场,造福全球病患。”

关于药明康德

药明康德(股票代码:603259/2359.HK)是国际领先的开放式能力与技能平台公司,为全球制药及医疗器械等范畴提供从药物发明、开辟到市场化的全方位一体化的尝试室研发和出产办事。本着以研究为首任,以客户为中间的宗旨,药明康德通过高性价比、高效率的办事平台帮忙全球客户缩短药物及医疗器械研发周期、降低研发成本。药明康德平台涵括小分子药物研发及出产、细胞疗法与基因疗法研产生产、医疗器械测试等,正承载着来自全球30多个国度的3500多家创新互助同伴的数千个研发创新项目,致力于将最新和最好的医药和康健产物带给全球病患,实现“让全国没有难做的药,难治的病”的空想。更多信息,请会见公司网站:

WuXi AppTec Named One of MIT Technology Review’s 50 Smartest Companies

Shanghai, June 29, 2019 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review’s 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its dedication in building an open-access R&D enabling platform for companies around the world to discover and develop new medicines for patients efficiently.

药明康德入选《麻省理工科技谈论》“50家智慧的公司”榜单

MIT Technology Review is one of the world’s preeminent technology publication and has been publishing this prestigious accolade since 2010. The 50 Smartest list was created to recognize companies that “best combine innovative technology with an effective business model.” TR50 demonstrates the innovative breakthroughs and significant impact that emerging technologies bring to the world.

Each year MIT Technology Review identifies 50 companies that are intelligently creating new opportunities by combining important technologies with a business savvy approach. The TR50 judging panel commented, “WuXi pioneered an open-access and integrated R&D platform, enabling thousands of customers to accelerate drug development. They have made a positive impact on innovation in the drug R&D industry globally.”

“It is our honor to be recognized by MIT Technology Review,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “At WuXi, our goal is to build the foundations upon which anyone, and any company, can be empowered to realize their innovation dreams. Collectively, we can continue to improve productivity, and bring new medicines to patients much faster.”

About WuXi AppTec

WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, the WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit:

您可能还会对下面的文章感兴趣: